Nicotine and Ulcerative Colitis: The Formulation Is the Claim

She quit smoking four years ago. Eleven months later she was told she had ulcerative colitis in her rectum and sigmoid, and two more years passed before she asked anyone whether she should start again.

The answer is no. Her observation is still not wrong, and the evidence on nicotine and ulcerative colitis turns out to be a measurement problem as much as a biology problem. I am Dr. Gurpreet Singh Padda, MD, MBA, MHP, and the video above is the final chapter of The Angry Gut, written with Ami Michelle Grimes. Below is what these trials measured, the one number nobody has taken, and where that leaves a terrain you can still change.

What quitting actually changed

Twelve observational studies were pooled for time to a first bowel resection. In ulcerative colitis, current smokers came out level with people who never smoked, at a hazard ratio for colectomy of 0.98 with an interval from 0.67 to 1.44. Lighting a cigarette today does not lower her odds of losing her colon. Former smokers carried 1.38, from 1.04 to 1.83. In Crohn’s disease the pattern flips: current smokers 1.27, from 1.08 to 1.49, and former smokers 1.11, from 0.95 to 1.30, an interval that crosses one.

Grade it before leaning on it. Reverse causation is live, because people quit for reasons that track how sick they already are. The studies used different definitions of a smoker, and none checked the answer against a blood test. The exposure was smoke, not the isolated alkaloid. Quitting is where the risk shows up, and relighting is not the road back.

The patch doses an entire body to reach one organ

A nicotine patch brought 17 of 35 patients with active colitis to complete remission, against 9 of 37 given placebo. In nonsmokers an independent group saw improvement in 39% against 9% by four weeks, with trough serum nicotine at 11.3 ng/mL as proof the drug arrived. Pooled, the patch beat placebo for induction at an odds ratio of 2.56.

Then the ceiling. Against prednisone or mesalamine there was no advantage, and the patch does not hold remission. A broader meta-analysis found no efficacy, a relative risk of 1.40 spanning one, while adverse events rose at 1.95. Side effects hit 23 of 35 patients against 11 of 37 on placebo, and mean trough cotinine reached 192 ng/mL. That is what a whole-body dose looks like in blood, and it is why the dose is capped by everything that is not the colon.

Two rectal preparations that are not the same drug

Merge the rectal work into one category and the argument collapses. Plain liquid nicotine tartrate barely enters the circulation: a detectable peak turned up in just 1 of 6 patients, at 2.3 ng/mL, while all six troughs were undetectable, and mean trough cotinine ran 13 ng/mL against 192 in the same group’s patch trial. Carbomer gel enemas do get in. In a 100 mL enema, 6 mg complexed with carbomer peaked in plasma at 8.1 ng/mL, with a median time to peak of 60 minutes, and cotinine peaked at 60.4 ng/mL at four hours, roughly seven times the parent peak.

So one group redesigned the vehicle instead of the molecule. Lowering the pH to 4.2 and thickening the gel cut the peak from 8.3 to 6.6 ng/mL while the mucosa met the same dose. Less free drug to absorb, the same amount against the tissue. That is formulation used as an instrument.

The one number nobody has taken

Here measurement fails the very argument it is meant to support. No study has ever measured nicotine concentration in rectal mucosal tissue. Every human study sampled serum, so the high local dose that justifies the whole route is an inference, never a demonstration where it counts.

What has been measured undercuts the simple version. Bioavailability across four liquid vehicles ran 15% to 25%, roughly matching the 20% obtained by swallowing a solution, and the loss is hepatic first pass rather than poor uptake by the lining. The most quoted mechanistic figure in this field, the ratio of cotinine exposure after oral against intravenous dosing at 1.5 and 1.6, rests on two subjects. Serum nicotine also failed to predict who felt unwell. A terrain argument lives or dies on what was actually assayed, the discipline a real metabolic audit applies to insulin and inflammation.

Nicotine and ulcerative colitis: absence of evidence is not a negative result

The randomized test failed, and I say so plainly. Remission reached 27% on nicotine enemas against 33% on placebo, the activity index improved 1.45 points on drug and 1.65 on placebo, and the authors called 6 mg enemas well tolerated but not efficacious. Local delivery did fix tolerability: of the 104 patients, exactly one stopped for an adverse event.

Two facts keep that from being a verdict on the route. No published trial of a nicotine suppository exists in any indication; the group that built formulations measured release across a cell monolayer and never put any of it into a living gut. And retention is the practical failure of the preparation that was tested, since 3 of 10 patients in the liquid pilot quit inside a week because they could not hold the enema. A drug expelled before it acts has not been tested.

The caution against my own reading belongs here too. A crossover scoring overnight retention found no difference on its primary comparisons, so retention fails some patients rather than all. And the lower rectum drains partly through veins that bypass the liver, so a suppository sitting low could deliver more drug per milligram than an enema reaching higher. That trade has never been measured, and an off-patent alkaloid with no sponsor gets no trial.

What to ask, and what actually repairs

There is an honest route to the anti-inflammatory receptor that involves giving nobody nicotine. In a rat model of ileus after surgery, a serotonin receptor agonist pushed cholinergic neurons to release more acetylcholine, which calmed the macrophages in the muscle layer; blocking the ganglion, or alpha-7 itself, abolished the benefit. That is rat work, and the drug that worked is serotonergic. The receptor can be reached by asking the nerve to do its own job rather than flooding it from outside.

So the useful questions are position and sequence. Where does the disease sit, distal or extensive, because every promising signal here lives on the left side of the colon. What has already been tried, because the single head-to-head win, 12 of 15 reaching remission against 5 of 15 on oral mesalamine at a p value of 0.027, was single-blind with no placebo and speaks only to distal disease that failed a rectal mesalamine. And when did symptoms begin relative to quitting, in months or years.

Then do not start. Not a cigarette, not a vape, not a patch bought for this purpose, and above all not a preparation made at home, where these studies show people feeling ill on doses that never reached their blood. Keep taking what you were prescribed and work every change through your own physician. Rescue is not repair, and the repair is the terrain, which is the thread from gut inflammation to joint pain and the reason the previous chapter in this series sits where it does. Every study named here is in the Chapter 32 Deep Dive.

Frequently asked questions

Does nicotine help ulcerative colitis?

Inconsistently, and at a cost. The patch beat placebo for inducing remission at an odds ratio of 2.56, then showed no advantage over prednisone or mesalamine and failed to hold remission, while a broader pool found no efficacy with adverse events rising at 1.95. Randomized enemas came in at 27% remission against 33% on placebo. Terrain decides what any single agent delivers.

Why did my colitis start after I quit smoking?

Ulcerative colitis is, epidemiologically, a disease of ex-smokers and non-smokers, and a cholinergic anti-inflammatory input that had reached your colon for years was withdrawn when you stopped. That is a physiological event with a named receptor rather than a coincidence, and it reframes the disease as a tendency a drug had been holding down. Say it out loud at your next appointment. The flora that regulate transit run on the same terrain.

Is a nicotine enema or suppository available?

No. Enemas existed only inside trials, and the 6 mg liquid vehicle that was tested came back negative. No nicotine suppository has been studied in a human being in any indication, so there is no product, no established dose, and nothing to copy at home. An absence of evidence licenses a trial, not a prescription. Nicotine does measurable things to healing tissue elsewhere.

Does vaping affect inflammatory bowel disease?

Nobody knows yet. A systematic review found four observational studies, 1,869 participants and 178 people who actually used the devices. In patients not having surgery there was no signal; after Crohn’s surgery, endoscopic recurrence at one year ran higher in device-only users than in nonsmokers without reaching significance. There is no randomized evidence, and the aerosol is not pharmaceutical nicotine. Repair is something the body does, and the terrain sets the ceiling.

Sources

1. Pullan, R. D., Rhodes, J., Ganesh, S., Mani, V., Morris, J. S., Williams, G. T., Newcombe, R. G., Russell, M. A., Feyerabend, C., & Thomas, G. A. (1994). Transdermal nicotine for active ulcerative colitis.. The New England Journal of Medicine, 330(12), 811-815. https://doi.org/10.1056/NEJM199403243301202
2. Sandborn, W. J., Tremaine, W. J., Offord, K. P., Lawson, G. M., Petersen, B. T., Batts, K. P., Croghan, I. T., Dale, L. C., Schroeder, D. R., & Hurt, R. D. (1997). Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial.. Annals of Internal Medicine, 126(5), 364-371. https://doi.org/10.7326/0003-4819-126-5-199703010-00004
3. McGrath, J., McDonald, J. W. D., & Macdonald, J. K. (2004). Transdermal nicotine for induction of remission in ulcerative colitis.. Cochrane Database of Systematic Reviews(4), CD004722. https://doi.org/10.1002/14651858.CD004722.pub2
4. Nikfar, S., Ehteshami-Ashar, S., Rahimi, R., & Abdollahi, M. (2010). Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis.. Clinical Therapeutics, 32(14), 2304-2315. https://doi.org/10.1016/j.clinthera.2011.01.004
5. Sandborn, W. J., Tremaine, W. J., Leighton, J. A., Lawson, G. M., Zins, B. J., Compton, R. F., Mays, D. C., Lipsky, J. J., Batts, K. P., Offord, K. P., Hurt, R. D., & Green, J. (1997). Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: A pilot study. Alimentary Pharmacology & Therapeutics, 11(4), 663-71. https://doi.org/10.1046/j.1365-2036.1997.00208.x
6. Green, J. T., Thomas, G. A., Rhodes, J., Evans, B. K., Russell, M. A., Feyerabend, C., Fuller, G. S., Newcombe, R. G., & Sandborn, W. J. (1997). Pharmacokinetics of nicotine carbomer enemas: A new treatment modality for ulcerative colitis. Clinical Pharmacology and Therapeutics, 61(3), 340-8. https://doi.org/10.1016/S0009-9236(97)90167-3
7. Green, J. T., Rhodes, J., Thomas, G. A., Evans, B. K., Feyerabend, C., Russell, M. A., & Sandborn, W. J. (1998). Nicotine carbomer enemas — pharmacokinetics of a revised formulation. Italian Journal of Gastroenterology and Hepatology, 30(3), 260-5. https://pubmed.ncbi.nlm.nih.gov/9759592/
8. Ingram, J. R., Thomas, G. A. O., Rhodes, J., Green, J. T., Hawkes, N. D., Swift, J. L., Srivastava, E. D., Evans, B. K., Williams, G. T., Newcombe, R. G., Courtney, E., & Pillai, S. (2005). A randomized trial of nicotine enemas for active ulcerative colitis.. Clinical Gastroenterology and Hepatology, 3(11), 1107-1114. https://doi.org/10.1016/s1542-3565(05)00849-9
9. Zins, B. J., Sandborn, W. J., Mays, D. C., Lawson, G. M., McKinney, J. A., Tremaine, W. J., Mahoney, D. W., Zinsmeister, A. R., Hurt, R. D., Offord, K. P., & Lipsky, J. J. (1997). Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. Journal of Clinical Pharmacology, 37(5), 426-36. https://doi.org/10.1002/j.1552-4604.1997.tb04320.x
10. Kuenzig, M. E., Lee, S. M., Eksteen, B., Seow, C. H., Barnabe, C., Panaccione, R., & Kaplan, G. G. (2016). Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration.. BMC Gastroenterology, 16(1), 143. https://doi.org/10.1186/s12876-016-0555-8

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 32 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.